CB Company

The new CanG law has opened the floodgates for proactive marketing towards new cannabis patients. Prescriptions are now available starting from 1€, necessary consultations and the shipping of medical cannabis take place entirely online, and rappers are promoting the whole thing. Is this in the interests of healthcare and patients? What do healthcare professionals and pharmaceutical companies say about this? And what is the position of the companies involved?

Moderator

• Bertan Türemis

Speakers

• Marla Luther
• Niels Lutzhoeft
• Gero Kohlhaas
• Matthias Fischer
• Janosch W. Kratz

With the new CanG, Germany has removed medical cannabis from the narcotics list. Doctors can now prescribe cannabis to patients without extensive bureaucratic hurdles, and at the same time, the cultivation of medical cannabis in Germany is permitted. What impact does this have on the market regarding prescription numbers for private and insured patients? How do patients benefit from this? What do doctors and pharmacies say about the new legislation?

Moderator

• Garvin Hirt

Speakers

• Leif Burmeister
• Christiane Neubaur
• Marcus Reussmann
• Nicole Perenyi

In addition to the recent partial legalization of cannabis in Germany, there is a lot happening around the globe: From Dutch and Swiss pilot projects to the advancements and plans in the Czech Republic, Poland, and other European countries, to Thailand, where politics may be vacillating, yet the cannabis economy is simultaneously flourishing and growing. Which country will legalize next? What are the latest future trends?

Moderator

• Georgia Glick

Speakers

• Alfredo Pascual
• Adele Hollmann
• Gavin George
• Nikita Cretu
• Elias Galantay

As of July 1, 2024, cultivation associations are allowed to grow cannabis for their up to 500 members and sell it to them without profit. As the "closing panels" of the preceding Intensive Seminar for Cultivation Associations (Cannabis Competence Days, CKT, Wednesday, June 12 – Thursday, June 13), experts from the fields of law, marketing, competition, and cultivation technology delve into the challenges posed by this law. What does it take to establish a cultivation association, grow high-quality cannabis, and distribute it successfully?
Moderator

• Dirk Rehahn

Speakers

• Marcus Geschwandter
• Christian Schmitt
• Marc Montandon
• Martin Anker
• Jörg Löser

As of April 1, 2024, Germany has decriminalized cannabis: possession, consumption, and personal cultivation are now penalty-free. Starting July 1, 2024, cultivation associations (colloquially known as "CSCs, Cannabis Social Clubs") are allowed to cultivate cannabis for up to 500 members and distribute it to their members non-profitably. Additionally, medical cannabis is no longer subject to the Narcotics Act and can now be prescribed by any doctor without the need for Btmg paperwork. What do these changes mean for Germany? Where are revisions urgently needed? And what are the chances for Phase 2, where model projects similar to Swiss pilot projects are planned?

Moderator

• Moritz Förster

Speakers

• Dirk Heitepriem
• Finn Hänsel
• Olivia Ewenike
• Dr. Philipp Goebel
• Timo Bongartz

This masterclass delves into the crucial role of genetics in cannabis production. Genetics dictate the quality, consistency, and cost of products—key factors for consumers. The panellists will discuss the surge in home cultivation in Europe, the seed versus tissue culture debate, and the complexities of aligning consumer tastes with genetic stability.

Additionally, the session explores the rise of first-time home growers, the creation of genetic banks, and the history of seed bank collecting. Legacy strains, their fit with current potency demands, and the intricacies of importing from North America are also examined. Addressing issues such as theft, licensing, and import/export limitations, this session offers a succinct insight into cannabis genetics for those eager to understand this evolving sector.

Language: English

Speakers

• Lily Temperton (Moderator), Tocar Strategic Advisors/ Hanway, Partner
• Ravi Dronkers (Speaker), Sensi Seeds, Head of Research and Development
• Dr. Gavin George (Speaker), Puregene AG, CEO
• Anthony Shevlin (Speaker), DéWarrior Unlimited B.V., head of agronomy
• Tim Oates (Speaker), Delta Tetra, TreeHouse, CEO, CCO

Since 2021, Max has been responsible for the lighting design and simulation of all major projects as Sales Application Engineer at SANlight GmbH. Here he can draw on his experience in climate and irrigation planning and provides customers with a holistic view of the project. Taking into account all influencing factors and components in a project of this magnitude is the key to success. Optimising energy consumption, Lich?ntensität during different growth phases and light distribution over the entire cultivation area are just a small part of the topics he can provide insight into. In the meantime, SANlight installations designed by Max can be found all over the world.

Language: English

Speaker

• Max von Knoop (Speaker), SANlight GmbH, M.A.; Field Application Engineer

IPM does not offer a universal remedy; rather, it involves the integration of customized strategies suited to individual circumstances. Through the implementation of these strategies, cultivators equip themselves with a robust methodology to effectively manage pests, pathogens, viruses and viroids.

Don't miss this opportunity to gain valuable insights into the realm of medical cannabis cultivation, as our panel of experts share their experiences in navigating the complexities of Integrated Pest Management (IPM) and the new threat of Hop Latent Viroid (HLVD).

Language: English

Speakers

• Jan Wegner (Moderator), Four 20 Pharma GmbH, Head of Cultivation
• Xavier Gaya (Speaker), Klonetics EU, Cultivation Advisor, Head of Sales
• Franz Josef Sima (Speaker), Fluence, Horticulture Service Specialist Cannabis
• Ben Niehaus (Speaker), SpexAI GmbH, Founder and CTO

Multiple informed choices in facility design have to be made by growers/investors. First of all the growing facility going for a indoor facility or a greenhouse facility. But secondly climate, light, substrate all are connected and as a consequence having impact on energy efficiency. All will be discussed in this panel with experts to achieve successful discussions on facility set-up.

Language: English

Speakers

• Sonny Moerenhout, (Moderator), Cultivators, Managing Partner
• Martin Anker (Speaker), SANlight GmbH, MSc.; CEO
• Marc Montandon (Speaker), CarbonActive GmbH, Owner
• Jörg Löser (Speaker), Cannafarm Arnstadt GmbH, CEO
• Ben Nikaj (Speaker), Grodan, Senior Crop Advisor

Join us as we introduce a diverse panel, bringing together different perspectives of the industry, to provide their insights on what the removal of cannabis from the German Narcotics List really means. What changes are to be expected by patients, pharmacists, physicians and the industry as a whole? Does the reclassification provide opportunities for the industry or is it just another reason for hype? We will take a closer look at this decision by the German government and discuss its implications.

Language: German

Speakers

• Bijan Christoph Hezarkhani (Moderator), BijanChristoph.com, Business Development
• Dr. Armin Prasch, (Speaker), Trias Pharma GmbH, CEO
• Thorsten Hetfeld (Speaker), CannaTHoC Cannabis-Association, Founder
• Melanie Dolfen, (Speaker), Bezirksapotheken Berlin, Pharmacist & Owner & Entrepreneur
• Garvin Hirt (Speaker), Copeia, Founding Partner